Involvement of Cytochrome P450 3A in the Metabolism and Covalent Binding of 14C-Monocrotaline in Rat Liver Microsomes

Journal of Biochemical and Molecular Toxicology

Volumn 12, Issue 3, 1998, Pages 157-166

  Reid, M J ^a   Lame M W ^a   Morin, D ^a   Wilson, D W ^a   Segall, H J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Autoradiography; Covalent Binding; Cytochrome P450 3A; Metabolism; Monocrotaline; Pyrrolizidine Alkaloid

Indexed keywords

STAPHYLOCOCCUS PHAGE 3A;

CARBON; CYTOCHROME P450; CYTOCHROME P450 3A; MONOCROTALINE; N DEMETHYLASE; UNSPECIFIC MONOOXYGENASE;

ANIMAL; ARTICLE; BINDING SITE; BIOSYNTHESIS; ENZYME INDUCTION; ENZYMOLOGY; LIVER MICROSOME; MALE; METABOLISM; RAT; SPRAGUE DAWLEY RAT;

ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BINDING SITES; CARBON RADIOISOTOPES; CYTOCHROME P-450 CYP3A; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INDUCTION; MALE; MICROSOMES, LIVER; MONOCROTALINE; OXIDOREDUCTASES, N-DEMETHYLATING; RATS; RATS, SPRAGUE-DAWLEY;

EID: 0031600208     PISSN: 10956670     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1099-0461(1998)12:3<157::aid-jbt4>3.3.co;2-u     Document Type: Article

References (53)

1. T. Hartmann and L. Witte (1995). Chemistry, biology and chemoecology of the pyrrolizidine alkaloids. In Alkaloids: Chemical and Biological Perspectives, S. W. Pelletier, ed., vol. 9, chap. 4, pp. 155-233, Pergamon Press, Tarrytown, NY.
2. L. B. Bull, C. C. J. Culvenor, and A. J. Dick (1968). Pyrrolizidine Alkaloids: Their Chemistry, Pathogenicity and Other Biological Properties, pp. 1-19, North-Holland, Amsterdam, The Netherlands.
3. R. J. Huxtable, A. Stillman, P. Consroe, P. Kohnen, and S. Smith (1977). Characterization of alkaloids involved in human pyrrolizidine (senecio) poisonings in Arizona. Gastroenterology, 73, 349-352.
4. A. R. Mattocks (1986). Chemistry and Toxicology of Pyrrolizidine Alkaloids, pp. 1-393, Academic Press, New York.
5. L. Carrillo and D. M. Aviado (1969). Monocrotaline-induced pulmonary hypertension and p-chlorophenylalanine (PCPA). Lab. Invest., 20, 243-248.
6. K. S. Hilliker, T. G. Bell, and R. A. Roth (1982). Pneumotoxicity and thrombocytopenia after a single injection of monocrotaline. Am. J. Physiol., 242, H573-579.
7. W. C. Miller, D. L. Rice, R. G. Kreusel, and W. M. Bedrossian (1978). Monocrotaline model of noncardiogenic pulmonary edema in dogs. J. Appl. Physiol., 45, 962-965.
8. C. F. Chesney and J. R. Allen (1973a). Monocrotaline induced pulmonary vascular lesions in non-human primates. Cardiovasc. Res., 7, 508-518.22.
9. D. W. Wilson, H. J. Segall, L. C. Pan, and S. K. Dunston (1989). Progressive inflammatory and structural changes in the pulmonary vasculature of MCT-induced rats. Microvasc. Res., 38, 57-80.
10. D. W. Wilson, H. J. Segall, L. C. Pan, M. W. Lamé, J. E. Estep, and D. Morin (1992). Mechanisms and pathology of monocrotaline pulmonary toxicity. Crit. Rev. Toxicol., 22, 307-325.
11. E. K. McClean (1970). The toxic actions of pyrrolizidine (senecio) alkaloids. Pharmacol. Rev., 22, 429-483.
12. H. M. Shulman, K. Luk, H. J. Deeg, W. B. Shulman, and R. Storb (1987). Induction of hepatic veno-occlusive disease in dogs. J. Am. Path., 126, 114-125.
13. A. R. Mattocks (1968). Toxicity of pyrrolizidine alkaloids. Nature, 217, 723-728.
14. H. J. Segall, M. W. Lamé, D. Morin, D. W. Wilson, and C. K. Winter (1991). Metabolism of pyrrolizidine alkaloids. In Toxicology of Plant and Fungal Toxins, R. F. Keeler and A. T. Tu, eds., vol. 6, pp. 3-26.
15. S. R. Dueker, M. W. Lamé, D. Morin, D. W. Wilson, and H. J. Segall (1992). Guinea pig and rat hepatic microsomal metabolism of monocrotaline. Drug Metab. Dispos., 20, 275-280.
16. A. R. Mattocks and I. N. H. White (1971). The conversion of pyrrolizidine alkaloids to N-oxides and to dihydropyrrolizine derivatives by rat-liver microsomes in vitro. Chem. Biol. Interact., 3, 383-396.
17. A. R. Mattocks (1972). Acute hepatotoxicity and pyrrolic metabolites in rats dosed with pyrrolizidine alkaloids. Chem. Biol. Interact., 5, 227-242.
18. D. F. Eastman, G. P. Dimenna, and H. J. Segall (1982). Covalent binding of two pyrrolizidine alkaloids, senecionine and seneciphylline, to hepatic macromolecules and their distribution, excretion and transfer into milk of lactating mice. Drug Metab. Dispos., 10, 236-240.
19. L. C. Pan, D. W. Wilson, M. W. Lamé, A. D. Jones, and H. J. Segall (1993). COR pulmonale is caused by monocrotaline and dehydromonocrotaline, but not by glutathione or cysteine conjugates of dihydropyrrolizine. Toxicol. Appl. Pharmacol., 118, 87-97.
20. M. W. Lamé, D. Morin, A. D. Jones, H. J. Segall, and D. W. Wilson (1990). Isolation and identification of a pyrrolic glutathione conjugate metabolite of the pyrrolizidine alkaloid monocrotaline. Toxicol. Lett., 51, 321-329.
21. 14C] monocrotaline by isolated perfused liver. Drug. Metab. Dispos., 19, 516-524.
22. C. L. Miranda, W. Chung, R. E. Reed, X. Zhao, M. C. Henderson, J. L. Wang, D. E. Williams, and D. R. Buhler (1991). Flavin-containing monooxygenase: a major detoxifying enzyme for the pyrrolizidine alkaloid senecionine in guinea pig tissues. Biochem. Biophys. Res. Com., 178, 546-552.
23. D. E. Williams, R. L. Reed, B. Kedzierski, G. A. Dannan, P. Guengerich, and D. R. Buhler (1989). Bioactivation and detoxication of the pyrrolizidine alkaloid senecionine by cytochrome P-450 enzymes in rat liver. Drug Metab. Dispos., 17, 387-392.
24. W. G. Chung and D. R. Buhler (1994). The effect of spironolactone treatment on the cytochrome P450-mediated metabolism of the pyrrolizidine alkaloid senecionine by hepatic microsomes from rats and guinea pigs. Toxicol. Appl. Pharmacol., 127, 314-319.
25. J. R. Halpert, F. P. Guengerich, J. R. Bend, and M. A. Correia (1994). Selective inhibitors of cytochromes P450. Toxicol. Appl. Pharmacol., 125, 163-175.
26. J. Brockmoller and I. Roots (1994). Assessment of liver metabolic function. Clinical implications. Clin. Pharmacokin., 27, 216-248.
27. N. A. Elshourbagy and P. S. Guzelian (1980). Separation, purification and characterization of a novel form of hepatic cytochrome P-450 from rats treated with pregnenolone-16 alpha-carbonitrile. J. Biol. Chem., 255, 1279-1285.
28. D. M. Heuman, E. J. Gallagher, J. L. Barwick, N. A. Elshourbagy, and P. S. Guzelian (1982). Immunochemical evidence for the induction of a common form of hepatic cytochrome P-450 in rats treated with pregnenolone-16 alpha-carbonitrile or other steroidal or non-steroidal agents. Molec. Pharmacol., 21, 753-760.
29. G. P. Vlasuk, J. Ghrayeb, D. E. Ryan, L. Reik, P. E. Thomas, W. Levin, and F. G. Walz Jr. (1982). Multiplicity strain differences, and topology of phenobarbital-induced cytochromes P450 in rat liver microsomes. Biochemistry, 21, 789-798.
30. S. A. Wrighton, P. Manuel, E. G. Schuetz, P. B. Watkins, B. Young, and P. S. Guzelian (1985). Identification of the cytochrome P-450 induced by macrolide antibiotics in rat liver as the glucocorticoid responsive cytochrome P-450p. Biochemistry, 24, 2171-2178.
31. J. K. Ritter and M. R. Franklin (1987). Induction and inhibition of rat hepatic drug metabolism by N-substituted imidazole drugs. Drug Metab. Dispos., 15, 335-343.
32. K. A. Hostetler, S. A. Wrighton, D. T. Molowa, P. E. Thomas, W. Levin, and P. S. Guzelian (1989). Coinduction of multiple hepatic cytochrome P-450 proteins and their mRNAs in rats treated with imidazole antimycotic agents. Molec. Pharmacol., 35, 279-285.
33. D. Pessayre, V. Descatoire, M. K. Mithcheva, J. C. Wandscheer, B. Covert, R. Level, J. P. Benhamou, M. Jaouen, and D. Mansuy (1981). Self induction by triacetyleandomycin of its own transformation into a metabolite forming stable 456 nm-absorbing complex with cytochrome P-450. Biochem. Pharmacol., 30, 553-558.
34. C. Bensoussan, M. De la Forge, and D. Mansuy (1995). Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs. Biochem. Pharmacol., 49, 591-602.
35. M. W. Lamé, D. Morin, D. W. Wilson, and H. J. Segall (1996). Methods to obtain radiolabelled monocrotaline. J. Labelled Compd. Radiopharm., 38, 1053-1060.
36. R. Adams and E. M. Rogers (1939). The structure of monocrotaline the alkaloid in Crotalaria spectabilis and C. retusa. J. Am. Chem. Soc., 1, 2815-2819.
37. M. W. Hoskins and D. H. G. Crout (1977). Pyrrolizidine alkaloid analogues: preparation of semisynthetic esters of retronecine. J. Chem. Soc. Perkin I, 538-544.
38. A. R. Mattocks (1969). Dihydropyrrolizine derivatives from unsaturated pyrrolizidine alkaloids. J. Chem. Soc. C, 1155-1162.
39. C. C. J. Culvenor and L. W. Smith (1957). The alkaloids of Crotalaria retusa L. Aust. J. Chem., 10, 464-473.
40. M. J. Reid, M. W. Lamé, D. Morin, D. W. Wilson, and H. J. Segall (1997). Monocrotaline metabolism and distribution in Fisher 344 and Sprague-Dawley rats. Comp. Biochem. Physiol., 117B, 115-123.
41. H. Uehleke (1971). N-hydroxylation. Xenobiotica, 1, 327-340.
42. J. Werringloer (1978). Assay of formaldehyde generated during microsomal oxidation reactions. Meth. Enzymol., 52, 297-302.
43. T. Omura and R. Sato (1964). The carbon monoxide-binding pigment of liver microsomes. J. Biol. Chem., 239, 2370-2385.
44. J. D. Sun and J. G. Dent (1980). A new method for measuring covalent binding of chemicals to cellular macromolecules. Chem. Biol. Inter., 32, 41-61.
45. O. H. Lowry, N. J. Rosebrough, A. L. Farr, and R. J. Randall (1951). Protein measurement with the folin phenol reagent. J. Biol. Chem., 193, 265-275.
46. A. Ghosal, N. Sadrieh, L. Reik, W. Levin, and P. E. Thomas (1996). Induction of the male-specific cytochrome P450 3A2 in female rats by phenytoin. Arch. Biochem. Biophys., 332, 153-162.
47. S. A. Wrighton, E. G. Schuetz, P. B. Watkins, P. Manuel, J. Barwick, B. S. Bailey, H. T. Hartley, B. Young, and P. Guzelian (1985). Demonstration in multiple species of inducible hepatic cytochromes P-450 and their mRNAs related to the glucocorticoid-inducible cytochrome P-450 of the rat. Molec. Pharmacol., 28, 312-321.
48. C. Mani, R. Pearce, A. Parkinson, and D. Kupfer (1994). Involvement of cytochrome P450 3A in catalysis of tamoxifen activation and covalent binding to rat and human liver microsomes. Carcinogenesis, 15, 2715-2720.
49. L. R. Shull, G. W. Buckmaster, and P. R. Cheeke (1976). Effect of pyrrolizidine alkaloids on liver microsome mixed-function oxidase activity in rats. J. Animal Sci., 43, 1024-1027.
50. L. H. Bruner, L. J. Carpenter, P. Hamlow, and R. A. Roth (1986). Effect of a mixed function oxidase inducer and inhibitor on monocrotaline pyrrole pneumotoxicity. Toxicol. Appl. Pharmacol., 85, 416-427.
51. K. S. Hillicker and R. A. Roth (1984). Alteration of monocrotaline-induced cardiopulmonary effects in rats by hydrallazine, dexamethasone or sulfinpyrazone. Brit. J. Pharmacol., 82, 375-380.
52. C. Brugnara, C. C. Armsby, M. Sakamoto, N. Rifai, S. L. Alper, and O. Platt (1995). Oral administration of clotrimazole and blockade of human erythrocyte Ca(+ +)-activated K+ channel: the imidazole ring is not required for inhibitory activity. J. Pharmacol. Exper. Therapeut., 273, 266-272.
53. L. C. Pan, M. W. Lamé, D. Morin, D. W. Wilson, and H. J. Segall (1991). Red blood cells augment transport of reactive metabolites of monocrotaline from liver to lung in isolated and tandem liver and lung perfusions. Toxicol. Appl. Pharmacol., 110, 336-346.